Loading…
Lantern Pharma Inc. is projected to rise to $4.09 by 2027, a +57% move from its current price of $2.61. LTRN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.50 | $2.61 | $2.73 | +0.09% |
| Aug 6 | $2.46 | $2.61 | $2.78 | +0.18% |
| Aug 7 | $2.42 | $2.62 | $2.82 | +0.28% |
| Aug 8 | $2.40 | $2.62 | $2.86 | +0.37% |
| Aug 9 | $2.38 | $2.62 | $2.89 | +0.46% |
| Aug 10 | $2.36 | $2.62 | $2.92 | +0.55% |
| Aug 11 | $2.34 | $2.63 | $2.95 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.34 | $2.63 | $2.95 | +0.64% |
| Week 2 | $2.24 | $2.64 | $3.12 | +1.29% |
| Week 3 | $2.17 | $2.66 | $3.26 | +1.95% |
| Week 4 | $2.12 | $2.68 | $3.38 | +2.60% |
| Week 5 | $2.08 | $2.70 | $3.50 | +3.27% |
| Week 6 | $2.04 | $2.71 | $3.61 | +3.93% |
| Week 7 | $2.01 | $2.73 | $3.72 | +4.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lantern Pharma Inc. is a healthcare company focused on the discovery and development of oncology drugs in India. Its product pipeline includes LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.
The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Lantern Pharma Inc. (LTRN) operates in Healthcare with a focus on oncology drug discovery and development, including LP-300, LP-184, LP-284, STAR-001, and an ADC program.
The current price is $2.60 and the market cap is $33.17M, with a rank of 4507. These figures position Lantern Pharma as a small-cap biotechnology player in a niche oncology development space.
The forecast suggests an upside path beyond the near term, with the 2026 avg price at $2.60 and a bullish trajectory unfolding through 2030 and beyond. For example, the 2030 avg is $7.04 and the 2050 avg is $51.68, with a max forecast of $118.86 in 2050. 2027 and later years show continued bullish momentum with progressively higher avg prices and ROIs, signaling meaningful upside over the long term.
A major floor 57.1% below — a decisive break under it would weaken the trend.
The nearest floor, 3.8% below — buyers have tended to step in here.
The nearest ceiling, 59.8% above — a clean break opens room to run.
A major ceiling 82.5% above — clearing it would confirm fresh momentum.
Key LTRN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LTRN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.64 | Sell | $2.65 | Sell |
| MA 10 | $2.75 | Sell | $2.76 | Sell |
| MA 20 | $3.02 | Sell | $2.98 | Sell |
| MA 50 | $3.45 | Sell | $3.15 | Sell |
| MA 100 | $2.84 | Sell | $3.10 | Sell |
| MA 200 | $3.10 | Sell | $3.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.55 | Neutral |
| Stoch RSI (14) | 52.96 | Neutral |
| CCI (20) | -88.14 | Neutral |
| Williams %R (14) | -79.66 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -15.16 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 20.34 | Neutral |
| TRIX (15) | -0.93 | Sell |
| Awesome (5,34) | -0.75 | Sell |
| Ultimate (7,14,28) | 30.25 | Neutral |
| Momentum (10) | -0.24 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 2.53 | Buy |
| ADX (14) | 23.70 | Sell |
| ATR (14) | 0.13 | Info |
The near-term technical picture is neutral. RSI14 is 40, and overall sentiment is NEUTRAL.
The 50-day simple moving average (SMA50) is $3.49 and the 200-day simple moving average (SMA200) is $3.15, with the current price sitting below both indicators. This suggests the stock could encounter resistance near the short-term moving averages.
Key support is at $2.79 and resistance at $4.17. The 30-day price range spans from $1.92 to $3.53, indicating recent price activity between these levels as traders assess near-term risk and opportunity.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.12 | $2.61 | $3.84 | 0% | Neutral | |
| $3.08 | $4.09 | $5.83 | +57% | Bullish | |
| $4.44 | $6.19 | $9.34 | +137% | Bullish | |
| $4.51 | $6.55 | $10.32 | +151% | Bullish | |
| $4.63 | $6.98 | $11.38 | +167% | Bullish | |
| $5.15 | $8.03 | $13.51 | +208% | Bullish | |
| $5.06 | $8.14 | $14.07 | +212% | Bullish | |
| $7.07 | $11.73 | $20.78 | +350% | Bullish | |
| $8.94 | $15.27 | $27.66 | +485% | Bullish | |
| $8.82 | $15.51 | $28.67 | +494% | Bullish | |
| $13.90 | $27.96 | $56.26 | +971% | Bullish | |
| $23.42 | $52.04 | $118.07 | +18.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.12 | $2.61 | $3.25 | +0.00% |
| September 2026 | $2.20 | $2.65 | $3.31 | +1.40% |
| October 2026 | $2.33 | $2.84 | $3.61 | +7.24% |
| November 2026 | $2.45 | $3.01 | $3.88 | +6.11% |
| December 2026 | $2.38 | $2.95 | $3.84 | -2.19% |
Click any year to see its month-by-month LTRN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect LTRN to range from $1.12 to $3.84 through 2026. The $2.61 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The LTRN price prediction for 2027 points to an average of $4.09 (low $3.08, high $5.83) — a potential gain of +57% on today's $2.61. Momentum favours further upside here.
In 2028, LTRN is projected to trade between $4.44 and $9.34, averaging $6.19 — a potential gain of +137% from today's $2.61. That is up +51% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Lantern Pharma Inc.'s 2029 outlook centres on $6.55, within a $4.51 to $10.32 range. That is up +6% on the projected 2028 average. That marks a +151% change versus current levels. Momentum favours further upside here.
By 2030, LTRN could reach as high as $11.38, with a base case around $6.98 and support toward $4.63 — roughly +167% from $2.61. Buyers look set to stay in control over this stretch.
Expect LTRN to range from $5.15 to $13.51 through 2031. The $8.03 average target implies a +208% move from current prices. That is up +15% on the projected 2030 average. Momentum favours further upside here.
The LTRN price prediction for 2032 points to an average of $8.14 (low $5.06, high $14.07) — a potential gain of +212% on today's $2.61. Buyers look set to stay in control over this stretch.
In 2033, LTRN is projected to trade between $7.07 and $20.78, averaging $11.73 — a potential gain of +350% from today's $2.61. That is up +44% on the projected 2032 average. Momentum favours further upside here.
Lantern Pharma Inc.'s 2034 outlook centres on $15.27, within a $8.94 to $27.66 range. That is up +30% on the projected 2033 average. That marks a +485% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, LTRN could reach as high as $28.67, with a base case around $15.51 and support toward $8.82 — roughly +494% from $2.61. Momentum favours further upside here.
Expect LTRN to range from $13.90 to $56.26 through 2040. The $27.96 average target implies a +971% move from current prices. That is up +80% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The LTRN price prediction for 2050 points to an average of $52.04 (low $23.42, high $118.07) — a potential gain of +18.9x on today's $2.61. Momentum favours further upside here.
Investing $1,000 in LTRN today (≈ 383.141762 LTRN) could be worth
$19,938.44
+$18,938.44 (+1894%) by 2050 · US Dollar
Based on the average projected LTRN price of $52.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LTRNwould be worth at today's price.
$1,000 invested in LTRN on Jul 31, 2025 (≈ 225.225222 LTRN) would be worth
$587.84
-$412.16 (-41.2%) today · 0.59× · US Dollar
Based on a LTRN entry price of $4.44 vs. today's $2.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.75 | $949.09 | -5.1% |
| 1 month ago | $4.02 | $649.25 | -35.1% |
| 3 months ago | $2.12 | $1,231.13 | +23.1% |
| 6 months ago | $3.06 | $852.94 | -14.7% |
| 1 year ago | $4.44 | $587.84 | -41.2% |
| All time (5.0y) ago | $12.96 | $201.39 | -79.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LTRN forecast.
Our base-case forecast reaches $5.20 around 2028.
Implied market cap at $5.20: $66.35M
The multi-year forecast shows a bullish trajectory with substantial upside over the horizon. By 2030, the expected average price is $7.04 and the ROI is 170.7, marking a strong growth path from the 2026 base of $2.60. In the 2040 window, the average is projected at $28.44 with an ROI of 993.8, underscoring a major expansion in value.
By 2050, the average is $51.68 with an ROI of 1887.6, with a maximum forecast of $118.86 tied to continued upside. The years 2027-2035 show progressively higher averages and bullish sentiment, culminating in sustained multi-year upside.
Drivers for the long-term outlook include LP-300 in phase 2, LP-184 in phase 1a, LP-284 in phase 1, STAR-001 in preclinical development, and an ADC program, complemented by AI-driven collaboration with Oregon Therapeutics and partnerships with TTC Oncology and Actuate Therapeutics. These factors support the potential for meaningful upside but these figures are estimates, not guarantees, and actual results will depend on clinical outcomes, regulatory developments, and market conditions.
Tap a question to reveal the answer.
The 2030 avg price is $7.04, with a min of $4.60 and a max of $11.66; ROI 170.7; sentiment BULLISH.
The forecast shows BULLISH sentiment from 2027 onward, with averages rising to $4.17 in 2027, $6.31 in 2028, and higher toward 2033–2050. The max forecast by 2050 is $118.86 and ROI reaches 1887.6; these are estimates, not guarantees.
Yes. The forecast max by 2050 is $118.86, which exceeds $100. This reflects potential upside in the long-term outlook, not a guaranteed outcome.
Current price is $2.60 and market cap is $33.17M. The rank is 4507.
Min $1.12, avg $2.60, max $3.84; ROI 0; sentiment NEUTRAL.
Lantern Pharma Inc. Community Discussion
0Share your Lantern Pharma Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.